Addex Therapeutics Ltd (0QNV.L)
- Globe Newswire
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022ADX71149 Phase 2 study in epilepsy cohort 1 completes part 1 – independent interim review committee (IRC) recommendation expected early Q2 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 30, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the full-ye
- Globe Newswire
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
Geneva, Switzerland, March 28, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its full-year 2022 financial results on Thursday, March 30, 2023. Tim Dyer, CEO and Robert Lütjens, Head of Discovery – Biology, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media
- Globe Newswire
Addex Announces Upcoming Conferences it will participate for H1 2023
Geneva, Switzerland, March 16, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will participate in the following conferences during the first half of 2023: Bio-Europe Spring: March 20 – 23, 2023; Basel, Switzerland.Swiss Biotech Day: April 24 – 25, 2023; Basel, Switzerland.Bio-Equity Europe: May 14 – 16, 2023; Dublin, Ireland Members of Addex management
